311 related articles for article (PubMed ID: 34607105)
21. Gold nanoparticle mediated cancer immunotherapy.
Almeida JP; Figueroa ER; Drezek RA
Nanomedicine; 2014 Apr; 10(3):503-14. PubMed ID: 24103304
[TBL] [Abstract][Full Text] [Related]
22. Delivery of Theranostic Nanoparticles to Various Cancers by Means of Integrin-Binding Peptides.
Egorova EA; Nikitin MP
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430214
[TBL] [Abstract][Full Text] [Related]
23. Ligand-targeted liposomes for cancer treatment.
Sapra P; Tyagi P; Allen TM
Curr Drug Deliv; 2005 Oct; 2(4):369-81. PubMed ID: 16305440
[TBL] [Abstract][Full Text] [Related]
24. To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery.
Danhier F; Feron O; Préat V
J Control Release; 2010 Dec; 148(2):135-46. PubMed ID: 20797419
[TBL] [Abstract][Full Text] [Related]
25. Multi-modal strategies for overcoming tumor drug resistance: hypoxia, the Warburg effect, stem cells, and multifunctional nanotechnology.
Milane L; Ganesh S; Shah S; Duan ZF; Amiji M
J Control Release; 2011 Oct; 155(2):237-47. PubMed ID: 21497176
[TBL] [Abstract][Full Text] [Related]
26. Functionalized nano-targeted moieties in management of prostate cancer.
Salaheldin TA; Bharali DJ; Mousa SA
Future Oncol; 2020 May; 16(13):869-883. PubMed ID: 32292071
[TBL] [Abstract][Full Text] [Related]
27. New molecular targets for functionalized nanosized drug delivery systems in personalized therapy for hepatocellular carcinoma.
Turato C; Balasso A; Carloni V; Tiribelli C; Mastrotto F; Mazzocca A; Pontisso P
J Control Release; 2017 Dec; 268():184-197. PubMed ID: 29051062
[TBL] [Abstract][Full Text] [Related]
28. Nanoplatform-based cascade engineering for cancer therapy.
Chen J; Zhu Y; Wu C; Shi J
Chem Soc Rev; 2020 Dec; 49(24):9057-9094. PubMed ID: 33112326
[TBL] [Abstract][Full Text] [Related]
29. Dual-targeting Wnt and uPA receptors using peptide conjugated ultra-small nanoparticle drug carriers inhibited cancer stem-cell phenotype in chemo-resistant breast cancer.
Miller-Kleinhenz J; Guo X; Qian W; Zhou H; Bozeman EN; Zhu L; Ji X; Wang YA; Styblo T; O'Regan R; Mao H; Yang L
Biomaterials; 2018 Jan; 152():47-62. PubMed ID: 29107218
[TBL] [Abstract][Full Text] [Related]
30. Advancement in integrin facilitated drug delivery.
Arosio D; Casagrande C
Adv Drug Deliv Rev; 2016 Feb; 97():111-43. PubMed ID: 26686830
[TBL] [Abstract][Full Text] [Related]
31. CRISPR-Cas13 System as a Promising and Versatile Tool for Cancer Diagnosis, Therapy, and Research.
Palaz F; Kalkan AK; Can Ö; Demir AN; Tozluyurt A; Özcan A; Ozsoz M
ACS Synth Biol; 2021 Jun; 10(6):1245-1267. PubMed ID: 34037380
[TBL] [Abstract][Full Text] [Related]
32. Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances.
Gandhi NS; Tekade RK; Chougule MB
J Control Release; 2014 Nov; 194():238-56. PubMed ID: 25204288
[TBL] [Abstract][Full Text] [Related]
33. Design of integrin α
Lv X; Zhang C; Shuaizhen Q; Yu R; Zheng Y
Biomed Pharmacother; 2020 Aug; 128():110236. PubMed ID: 32447209
[TBL] [Abstract][Full Text] [Related]
34. Filamentous bacteriophage: A prospective platform for targeting drugs in phage-mediated cancer therapy.
Garg P
J Cancer Res Ther; 2019 Mar; 15(Supplement):S1-S10. PubMed ID: 30900613
[TBL] [Abstract][Full Text] [Related]
35. Nanotechnology approaches for personalized treatment of multidrug resistant cancers.
Minko T; Rodriguez-Rodriguez L; Pozharov V
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1880-95. PubMed ID: 24120655
[TBL] [Abstract][Full Text] [Related]
36. Cancer/Testis Antigens: Expression, Regulation, Tumor Invasion, and Use in Immunotherapy of Cancers.
Salmaninejad A; Zamani MR; Pourvahedi M; Golchehre Z; Hosseini Bereshneh A; Rezaei N
Immunol Invest; 2016 Oct; 45(7):619-40. PubMed ID: 27603913
[TBL] [Abstract][Full Text] [Related]
37. Cell-derived Exosomes as Promising Carriers for Drug Delivery and Targeted Therapy.
Wang X; Zhang H; Yang H; Bai M; Ning T; Li S; Li J; Deng T; Ying G; Ba Y
Curr Cancer Drug Targets; 2018; 18(4):347-354. PubMed ID: 28699500
[TBL] [Abstract][Full Text] [Related]
38. Nanotechnology applications in cancer.
Nie S; Xing Y; Kim GJ; Simons JW
Annu Rev Biomed Eng; 2007; 9():257-88. PubMed ID: 17439359
[TBL] [Abstract][Full Text] [Related]
39. Synthetic Lethality: From Research to Precision Cancer Nanomedicine.
Gupta A; Ahmad A; Dar AI; Khan R
Curr Cancer Drug Targets; 2018; 18(4):337-346. PubMed ID: 28669337
[TBL] [Abstract][Full Text] [Related]
40. A targeted nanoplatform co-delivering chemotherapeutic and antiangiogenic drugs as a tool to reverse multidrug resistance in breast cancer.
Tian F; Dahmani FZ; Qiao J; Ni J; Xiong H; Liu T; Zhou J; Yao J
Acta Biomater; 2018 Jul; 75():398-412. PubMed ID: 29874597
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
